EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS
High Risk (>90% frequency without antiemetics)
AC combination: Doxorubicin (Adriamycin) or Epirubicin (Ellence) Cyclophosphamide (Cytoxan, Neosar) Altretamine (HMM, Hexalen) Carmustine (BCNU, BiCNU) 250mg/m2 Cisplatin (CDDP, Platinol, Platinol-AQ) 50mg/m2 Cyclophosphamide (CTX, Cytoxan, Neosar) 1,500mg/m2 Dacarbazine (DTIC, DTIC-Dome) Aldesleukin (IL-2, Proleukin) 1215 million units/m2 Amifostine (Ethyol) 300mg/m2 Arsenic trioxide (As2O3, Trisenox) Azacitidine (Vidaza) Bendamustine (Treanda) Busulfan (Busulfex) IV, oral 4mg/d Carboplatin (Paraplatin) Carmustine (BCNU, BiCNU) 250mg/m2 Cisplatin (CDDP, Platinol, Platinol-AQ) 50mg/m2 Clofarabine (Clolar) Cyclophosphamide (CTX, Cytoxan, Neosar) 1,500mg/m2 Cyclophosphamide (CTX) oral 100mg/m2/d Cytarabine (ARA-C, Cytosar-U) 200mg/m2 Dactinomycin (actinomycin D, Cosmegen) Daunorubicin (Cerubidine, Daunomycin) Aldesleukin (IL-2, Proleukin) 12 million units/m2 Amifostine (Ethoyl) 300mg Bexarotene (Targretin) Cabazitaxel (Jevtana) Capecitabine (Xeloda) oral Cetuximab (C225, Erbitux) Cyclophosphamide (CTX) oral 100mg/m2/d Cytarabine (ARA-C, Cytosar-U) 100200mg/m2 Docetaxel (Taxotere) Doxorubicin liposomal (Doxil) Eribulin (Halaven) Etoposide (VP-16, Etopophos, VePesid) IV Floxuridine Fludarabine (Fludara) oral Fluorouracil (5-FU) Alemtuzumab (Campath) Asparaginase (Elspar) Bevacizumab (Avastin) Bleomycin (Blenoxane) Bortezomib (Velcade) Busulfan (Busulfex) oral 4mg/d Cetuximab (Erbitux) Chlorambucil (Leukeran) oral Cladribine (2-CdA, Leustatin) Cytarabine (ARA-C, Cytosar-U) 100mg/m2 Dasatinib (Sprycel) Decitabine (Dacogen) Denileukin diftitox (Ontak) Dexrazoxane (Totect, Zinecard) Erlotinib (Tarceva) Everolimus (Afinitor, Zortress) Fludarabine (Fludara) IV Gefitinib (Iressa) Hydroxyurea (Hydrea) oral Imatinib (Gleevec) Interferon alpha (IFN-alfa, Intron A) 5 million units/m2 Ipilimumab (Yervoy) Lapatinib (Tykerb) Lenalidomide (Revlimid) Melphalan (L-PAM, Alkeran) low dose oral Doxorubicin (Adriamycin) >60mg/m2 Epirubicin (Ellence) >90mg/m2 Ifosfamide (Ifex) >10g/m2 Mechlorethamine (Mustargen) Procarbazine (Matulane) oral Streptozocin (Zanosar) Doxorubicin (Adriamycin) 60mg/m2 Epirubicin (Ellence) 90mg/m2 Estramustine (Emcyt) Etoposide (VP-16, VePesid) oral Idarubicin (Idamycin) Ifosfamide (Ifex) 10g/m2 Interferon alpha (IFN-alfa, Intron A) 10 million units/m2 Irinotecan (CPT-11, Camptosar) Lomustine (CCNU, CeeNU) Melphalan (L-PAM, Alkeran) 50mg/m2 IV Methotrexate (MTX) 250mg/m2 Oxaliplatin (Eloxatin) 75mg/m2 Temozolomide (Temodar) oral 75mg/m2/d Vinorelbine (Navelbine) oral Gemcitabine (Gemzar) Interferon alpha (IFN-alfa, Intron A) 510 million units/m2 Ixabepilone (Ixempra) Methotrexate (MTX) 50mg/m2 to 250mg/m2 Mitomycin (MTC, Mitozytrex, Mutamycin) Mitoxantrone (DHAD, Novantrone) Paclitaxel (Taxol) Paclitaxel albumin (Abraxane) Pemetrexed (Alimta) Pentostatin (Nipent) Pralatrexate (Folotyn) Romidepsin (Istodax) Thiotepa Topotecan (Hycamtin) IV, oral Mercaptopurine (purinethol) Methotrexate (MTX) 50mg/m2 IV, oral Nelarabine (Arranon) Niltoinib (Tasigna) Ofatumumab (Arzerra) Panitumumab (Vectibix) Pazopanib (Votrient) Pegasparagase (Oncaspar) Peginterferon Rituximab (Rituxan) Sorafenib (Nexavar) Sunitinib (Sutent) Temsirolimus (Torisel) Temozolamide (Temodar) 75mg/m2/d Tretinoin (Vesanoid) Thalidomide (Thalomid) Thioguanine (6-TG,Tabloid) oral Trastuzumab (Herceptin) Valrubicin (Valstar) Vandetanib (Caprelsa) Vinblastine (VLB) Vincristine (VCR) Vinorelbine (Navelbine) IV Vorinostat (Zolinza)
Moderate Risk (3090% frequency without antiemetics)
Low Risk (1030% frequency without antiemetics)
Minimal Risk (<10% frequency without antiemetics)
NOTES
*Daily use of antiemetics is not recommended based on clinical experience. Adapted from: 1. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24:2932-2947. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology; v.1.2012: Antiemesis. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed August 8, 2012. (Rev. 8/2012)
